During the first ten weeks of my project, I was able to study a variety of clinical trials that target amyloid beta as a treatment for Alzheimer’s disease. Amyloid centered treatments have been the focus of the industry for years although none have seemed to delivered results. My goal was to study the reasons of the failure of these trials and to evaluate if these failures meant that a revaluation of the amyloid cascade is necessary.

For the last five weeks of the project, I studied one clinical trial called Aducanumab. This trial was the most promising as it was given to two different groups and one of the groups called EMMERGE obtained positive results concerning the drug whilst ENGAGE, the other group, obtained negative results.